Inclusion Criteria:

- Patients receiving a central venous catheter for chemotherapy of AML or ALL

- Patients receiving a central venous catheter for high-dose chemotherapy with
consecutive autologous stem cell transplantation or any other condition with an
expected duration of chemotherapy-associated neutropenia of at least 5 days and an
expected duration of central venous catheter use of at least 10 days

- Age >= 18 years

Exclusion Criteria:

- Condition with an expected duration of chemotherapy-associated neutropenia of at less
than 5 days and an expected duration of central venous catheter use of less than 10
days

- Use of a central venous catheter with antimicrobial coating other than chlorhexidine
and/or silver-sulfadiazine

- Limited venous status, impeding acquisition of peripheral blood cultures in case of
febrile neutropenia

- Patients previously enrolled in the study

- Tunneled central venous catheters

- Shaldon catheters

- CVC insertion via the V. femoralis

- Fever (T > 37.8°C) related to a suspected or confirmed bacterial infection at
randomization

- Known allergic/hypersensitivity reaction to any compounds of the treatment

- Legal incapacity or limited legal capacity

- Medical or psychological condition which in the opinion of the investigator would not
permit the patient to complete the study or sign meaningful informed consent